Pfizer Inc. news

   Watch this stock
Showing stories 11 - 20 of about 231   

Articles published

PFE 34.04 -0.13 (-0.38%)
price chart
Pfizer (PFE) Commences Phase 1 Clinical Trial to Evaluate Investigational ...
Pfizer Inc. (NYSE: PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection.
Why I Went Long Pfizer
Dividend growth history is solid with the exception of a cut after the Wyeth acquisition. The yield investors can get here is much higher than what we get from the broad market or Treasuries.
Better Buy: Pfizer Inc. vs. Johnson & Johnson
Pfizer's Ibrance didn't earn Food and Drug Administration approval until 2015, but first-quarter sales of the breast cancer therapy put it on pace to reach $2.7 billion this year.
Basilea Announces Distribution Agreements with Pfizer and Avir Pharma Inc
On June 14, 2017, Basilea Pharmaceutica Ltd. announced that it had entered into agreements with Pfizer Inc. and Canadian pharmaceutical company Avir Pharma Inc. to distribute and license Basilea's antifungal Cresemba (isavuconazole).
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug  Nasdaq
Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA  The FINANCIAL
EOD Risers: Pfizer Inc., United Technologies Corporation, UnitedHealth Group Inc
Shares of Pfizer Inc. ticker code: (NYSE:PFE) a research-based global biopharmaceutical company, moved up 0.95% or 0.32 points by the close of business yesterday.
Focusing The Bull-Eye on Shares Pfizer Inc. (NYSE:PFE)
The Current Ratio of Pfizer Inc. (NYSE:PFE) is 1.44. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts.
Buy or Sell? Average Brokerage Ratings on Twitter, Inc. (TWTR), Pfizer Inc. (PFE)
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.
Pfizer, Lilly granted accelerated review for non-opioid pain drug
US regulators have granted Pfizer and Eli Lilly an accelerated review for a new type of drug for chronic pain at a time when America is grappling an opioid epidemic.
Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab  Business Wire (press release)
Pfizer hikes US prices of 91 drugs by average 20 percent in 2017: Financial Times
Pfizer Inc (PFE.N) has hiked the price of nearly a hundred drugs by an average of 20 percent so far this year in the United States, the Financial Times reported on Friday.
Pfizer shrugs off potential ire from politicians; hikes prices 20%  Seeking Alpha
Pfizer raises US prices of 91 drugs by 20% in 2017  Financial Times
A Chartists Perspective on Pfizer Inc (PFE)
Traders may be keeping a close eye on ATR indicators. The current 14-day ATR for Pfizer Inc (PFE) is currently sitting at 0.40.
A Chartists Perspective on PFIZER INC. DL-05 (PFE.DE)  Piedmont Register